HT-0712 vs. Placebo in Subjects With Age-Associated Memory Impairment (AAMI)
NCT ID: NCT02013310
Last Updated: 2015-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
119 participants
INTERVENTIONAL
2013-12-31
2015-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HT-0712 (50mg)
HT-0712 capsules administered once daily.
HT-0712
Placebo
Placebo capsules administered once daily.
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HT-0712
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Performance at least one standard deviation below the mean established for young adults on standardized memory tests
* Absence of dementia
* Intact global intellectual function
Exclusion Criteria
* Evidence of dementia
* Evidence of psychiatric or neurological disorder that could influence cognition or contributed to the subject's memory loss
* Use of any drugs that could influence cognition
50 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dart NeuroScience, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philip Perera, MD
Role: STUDY_DIRECTOR
Dart NeuroScience, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun City, Arizona, United States
Long Beach, California, United States
Santa Monica, California, United States
Denver, Colorado, United States
Atlantis, Florida, United States
Brooksville, Florida, United States
Tampa, Florida, United States
Marlton, New Jersey, United States
Princeton, New Jersey, United States
New York, New York, United States
Dayton, Ohio, United States
Tulsa, Oklahoma, United States
Cordova, Tennessee, United States
Austin, Texas, United States
San Antonio, Texas, United States
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HT-0712-201
Identifier Type: -
Identifier Source: org_study_id